Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways which is currently under phase 3 clinical trials for its lead indication to reduce post-operative complications following cardiothoracic surgery.
Lead Product(s): Stannic Protoporfin,Iron Sucrose
Therapeutic Area: Cardiology/Vascular Diseases Product Name: RBT-1
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surgery.
Lead Product(s): Stannic Protoporfin,Iron Sucrose
Therapeutic Area: Cardiology/Vascular Diseases Product Name: RBT-1
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
Details:
The proceeds will advance RBT-1 through a pivotal Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surgery. RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Product Name: RBT-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Juniper Point
Deal Size: $72.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 12, 2023
Details:
The proceeds will advance RBT-1 (stannic protoporfin/iron sucrose), a potent inducer of anti-inflammatory, antioxidant and iron scavenging pathways, through Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surgery.
Lead Product(s): Stannic Protoporfin,Iron Sucrose
Therapeutic Area: Cardiology/Vascular Diseases Product Name: RBT-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $47.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 18, 2023
Details:
RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways that is advancing toward for its lead indication to reduce post-operative complications following cardiothoracic surgery.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Product Name: RBT-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
RBT-1 (Iron sucrose), treated patients demonstrated a highly significant increase in anti-inflammatory and antioxidant biomarkers of cytoprotective preconditioning. The biomarkers assessed were interleukin-10, heme oxygenase-1 and ferritin.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Product Name: RBT-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
RBT-1 (Iron Sucrose) met primary endpoint of increasing the expression of biomarkers of cytoprotective preconditioning; positive data supports the potential for RBT-1 to impact clinical outcomes in cardiothoracic surgery patients.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Product Name: RBT-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2022
Details:
Proceeds from the recent financing will be used to advance Renibus’ pipeline, including the company’s lead candidates, RBT-1 for prevention of acute kidney injury (AKI), currently in a large (126 patients), randomized, double-blind study in AKI in a cardiac surgery setting.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Product Name: RBT-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 15, 2022
Details:
This Phase 2 study will evaluate the efficacy of RBT-1 in generating a preconditioning response as measured by a composite of biomarkers in subjects who are at risk for AKI following cardiac surgery.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: RBT-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2021
Details:
Rénibus Therapeutics will present Phase 1b clinical trial data on RBT-1, its investigational treatment for the prevention of acute kidney injury (AKI), at the Acute Kidney Injury & Continuous Renal Replacement Therapy (AKI & CRRT) 2021 Conference.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: RBT-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2021